S&T-35 EXOSOMAL MIRNAS AND SERUM CYTOKINES AS PREDICTORS FOR TREATMENT OUTCOMES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH AXITINIB

Abstract

You have accessJournal of UrologyScience & Technology Posters1 Apr 2016S&T-35 EXOSOMAL MIRNAS AND SERUM CYTOKINES AS PREDICTORS FOR TREATMENT OUTCOMES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH AXITINIB Naoko Suzuki-Honma, Norihiko Tsuchiya, Takamitsu Inoue, Shintaro Narita, Mitsuru Saito, Hiroshi Tsuruta, Atsushi Maeno, Shigeru Satoh, and Tomonori Habuchi Naoko Suzuki-HonmaNaoko Suzuki-Honma More articles by this author , Norihiko TsuchiyaNorihiko Tsuchiya More articles by this author , Takamitsu InoueTakamitsu Inoue More articles by this author , Shintaro NaritaShintaro Narita More articles by this author , Mitsuru SaitoMitsuru Saito More articles by this author , Hiroshi TsurutaHiroshi Tsuruta More articles by this author , Atsushi MaenoAtsushi Maeno More articles by this author , Shigeru SatohShigeru Satoh More articles by this author , and Tomonori HabuchiTomonori Habuchi More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2864AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Axitinib (AXI), which selectively inhibits VEGF-Rs, is one of the promising molecular targeted drugs for metastatic renal cell carcinoma (mRCC). However, novel biomarkers to predict for patient outcomes are urgently needed because there are individual differences in treatment response. Here, we investigated the relationship between exosomal microRNAs, serum cytokines, and clinical outcomes in patients with mRCC treated with AXI. METHODS Serum samples at baseline and at 4 weeks after AXI treatment were extracted from total of 32 patients with mRCC treated with AXI between September 2012 and October 2014 at Akita University Hospital. The expression levels of 4 exosomal microRNAs (miR-21, miR-155, miR-210, miR-378) were evaluated by quantitative RT-PCR. The levels of 34 cytokines were measured by Bio-Plex Pro TM Human Cancer Biomarker Panels. The relationship between exosomal microRNAs, serum cytokines and clinical outcomes including response rate and progression free survival (PFS) after AXI treatment was statistically assessed. RESULTS 43.8% patients had a partial response to AXI. Median PFS was 7.4 months. The patients with a higher expression level of miR-378 at baseline had a significantly better tumor response rate than those with a lower expression level of miR-378 (p = 0.048), while the patients with a lower expression level of miR-21 at baseline had a significantly longer PFS than those with a higher expression level of miR-21 (p = 0.019). The patients with higher expression levels of serum HGF, IL-6R, and PECAM-1 at baseline had a significantly longer PFS than those with a lower expression of these cytokines (p = 0.043, p = 0.033, p = 0.002, respectively). Decreased expression of serum IL-8 and TGF-alpha at 4weeks after AXI treatment were significantly associated with longer PFS (p = 0.020, p = 0.025, respectively). The exosomal microRNAs at 4 weeks after AXI treatment were not significantly associated with clinical outcomes in patients with mRCC. CONCLUSIONS Pretreatment exosomal microRNAs and serum cytokines may be potential predictive biomarkers in patients with mRCC treated with AXI. Personalized medicine using these biomarkers is useful for selecting effective drugs in patient with mRCC. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e322-e323 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Naoko Suzuki-Honma More articles by this author Norihiko Tsuchiya More articles by this author Takamitsu Inoue More articles by this author Shintaro Narita More articles by this author Mitsuru Saito More articles by this author Hiroshi Tsuruta More articles by this author Atsushi Maeno More articles by this author Shigeru Satoh More articles by this author Tomonori Habuchi More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...